Regulation
Novocure receives CE mark for Optune Pax device
Novocure received CE Mark approval for Optune Pax, a portable device designed to treat adults with locally advanced exocrine pancreatic cancer. The clearance enables the company to market the device in the European Union and other regions that recognize CE certification.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network